Hopitaux Prives De Metz — Clinical Trial Site

38 Registered trials

16 Currently recruiting

Organisation

Hopitaux Prives De Metz

Location

Vantoux, France

Identifier

ORG-100043189

Address

Rue Du Pre Montois, 57070, France

Departments

2305:Pneumologie
Cancérologie-pneumologie
Chirurgie gynécologique & sénologique
Département de Pneumologie
Internal Medicine
Médecine interne
Medical Oncology
N/A
Oncologie
Oncologie Médicale
Oncology
Oncology Unit
Pneumologie
Pneumology
Pulmonology department
Service d'Oncologie
Service de Pneumologie
Service de Réanimation Polyvalente
Service Pneumologie

Clinical trials at this site (38)

Search interface

A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended

2023-507494-18-00 Non-small cell lung cancer with ROS proto-oncogene 1, r 5 2021-09-24
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Muscle Invasive Bladder Cancer 5 2019-06-04
A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended

2023-509576-42-00 Patients with resectable Non-small Cell Lung Cancer (St 5 2019-02-21
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted

2024-516687-28-00 Patients with GPA and inadequate response to standard o 5 2025-06-06
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended

2024-513648-27-00 Patients with newly or active diffuse Systemic sclerosi 4 2024-10-25
A Study to Investigate MBS2320 Patients with IPF Ended

2023-504418-30-00 Idiopathic Pulmonary Fibrosis 4 2023-10-24
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel… Ended

2022-502480-38-00 Non−small cell lung cancer (NSCLC) 5 2020-09-09
Pragmatic management of progressive disease in idiopathic pulmonary fibrosis Ended

2024-511427-34-00 idiopathic pulmonary fibrosis 5 2020-02-20
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 5 2019-06-26
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 5 2019-06-25
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended

2022-501970-20-01 Cis-eligible Muscle-invasive bladder cancer. 5 2019-06-07